Literature DB >> 15776005

Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Weiping Zou1.   

Abstract

It is well known that many tumours are potentially immunogenic, as corroborated by the presence of tumour-specific immune responses in vivo. Nonetheless, spontaneous clearance of established tumours by endogenous immune mechanisms is rare. Therefore, the focus of most cancer immunotherapies is to supplement essential immunogenic elements to boost tumour-specific immunity. Why then has tumour immunotherapy resulted in a generally poor clinical efficiency? The reason might lie in the increasingly documented fact that tumours develop diverse strategies that escape tumour-specific immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15776005     DOI: 10.1038/nrc1586

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  726 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Analysis of FoxP3+ T-regulatory cells and CD8+ T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers.

Authors:  Cecilia Hermans; David Anz; Jutta Engel; Thomas Kirchner; Stefan Endres; Doris Mayr
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

3.  Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Authors:  Asa Andersson; Minu K Srivastava; Marni Harris-White; Min Huang; Li Zhu; David Elashoff; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2011-06-01       Impact factor: 12.531

4.  Reversal of gastrointestinal carcinoma-induced immunosuppression and induction of antitumoural immunity by a combination of cyclophosphamide and gene transfer of IL-12.

Authors:  Mariana Malvicini; Mariana Ingolotti; Flavia Piccioni; Mariana Garcia; Juan Bayo; Catalina Atorrasagasti; Laura Alaniz; Jorge B Aquino; Jaime A Espinoza; Manuel Gidekel; O Graciela Scharovsky; Pablo Matar; Guillermo Mazzolini
Journal:  Mol Oncol       Date:  2011-04-05       Impact factor: 6.603

Review 5.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 6.  Therapeutic dormancy to delay postsurgical glioma recurrence: the past, present and promise of focal hypothermia.

Authors:  Didier Wion
Journal:  J Neurooncol       Date:  2017-05-17       Impact factor: 4.130

7.  Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Takuo Hasegawa; Kohei Ichihara; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  Mol Clin Oncol       Date:  2017-04-04

Review 8.  T lymphocytes targeting native receptors.

Authors:  Cliona M Rooney; Ann M Leen; Juan F Vera; Helen E Heslop
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Authors:  Michael Y Gerner; Matthew F Mescher
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

10.  Eya3 promotes breast tumor-associated immune suppression via threonine phosphatase-mediated PD-L1 upregulation.

Authors:  Rebecca L Vartuli; Hengbo Zhou; Lingdi Zhang; Rani K Powers; Jared Klarquist; Pratyaydipta Rudra; Melanie Y Vincent; Debashis Ghosh; James C Costello; Ross M Kedl; Jill E Slansky; Rui Zhao; Heide L Ford
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.